FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556227380> ?p ?o ?g. }

• W2556227380 abstract "Abstract Abstract 3699 Background: Radiotherapy is considered the standard approach in stage I-II non bulky FL but no consensus of the required radiation field has been reached and failure-free survival (FFS) reported ranged between 41 to 49%. Published randomized trials failed to demonstrate the superiority of non adriamycin-containing regimens plus RT over RT alone and only one single arm study with COP-B plus IF-RT reported superior FFS (73%) however complicated by an high rate of treatment related toxicity. Since the monoclonal anti CD-20 antibody Rituximab has shown to be effective in systemic therapy of FL as primary treatment as well at relapse, the combination of the anti-CD20 Rituximab with IF-RT may be considered a valid approach, allowing an effective systemic disease control while sparing the toxicity of chemotherapy. We reported here the long-term outcome of a series of stage I-II FL pts treated front-line with Rituximab followed by IF-RT. Patients and Methods: From July 1999 to April 2009, 36 consecutive stage I-II FL WHO grade I-II, have been enrolled in this phase II study and treated with 4 weekly doses of Rituximab followed by IF-RT. Median age: 49 yrs (range 34–82), M/F: 20/16; FLIPI 0–1: 36; Bulky:0. BM PCR analysis to detect minimal residual disease (MRD) was carried out in 25 pts with a molecular probe: PCR+/PCR-: 10/15. Treatment consisted of 4 weekly doses of Rituximab (375 mg/sqm) followed by external bean RT on involved fields. Median radiation dose was 30.6 Gy, (range 20–40). Results: Rituximab followed by IF-RT was well tolerated without any additional toxicity. All but one pts reached a complete remission (CR). With a median follow-up of 7 years (range: 2–12), 34 pts are alive and 24 in continuous complete remission. Of the 12 relapsed pts, 6 were PCR+ versus 4 PCR- at baseline BM analysis; 2 pts had no molecular probe. Two smokers pts died of lung cancer at 3 and 4 years after immuno-radiotherapy. The OS and FFS were 94% and 67% respectively. These results compare favorably with those observed in similar historical control group treated at our Institution with IF-RT alone (OS:87%,FFS:46.8%). Conclusion: Rituximab followed by IF-RT is a well tolerated and effective front-line treatment for limited stage FL. Long-term results are comparable to those reported for non-anthracycline-containing chemo-radiotherapy and higher when compared to radiotherapy alone, making Rituximab-IF-RT a potential option as initial therapy of limited stage FL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2556227380 created "2016-11-30" @default.
• W2556227380 creator A5030934542 @default.
• W2556227380 creator A5052878762 @default.
• W2556227380 creator A5058765211 @default.
• W2556227380 creator A5060509370 @default.
• W2556227380 creator A5064710359 @default.
• W2556227380 creator A5066576514 @default.
• W2556227380 creator A5068769311 @default.
• W2556227380 creator A5071803772 @default.
• W2556227380 creator A5077428267 @default.
• W2556227380 creator A5086614200 @default.
• W2556227380 creator A5087294312 @default.
• W2556227380 creator A5087360250 @default.
• W2556227380 creator A5088355904 @default.
• W2556227380 date "2011-11-18" @default.
• W2556227380 modified "2023-10-16" @default.
• W2556227380 title "Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results," @default.
• W2556227380 doi "https://doi.org/10.1182/blood.v118.21.3699.3699" @default.
• W2556227380 hasPublicationYear "2011" @default.
• W2556227380 type Work @default.
• W2556227380 sameAs 2556227380 @default.
• W2556227380 citedByCount "1" @default.
• W2556227380 countsByYear W25562273802012 @default.
• W2556227380 crossrefType "journal-article" @default.
• W2556227380 hasAuthorship W2556227380A5030934542 @default.
• W2556227380 hasAuthorship W2556227380A5052878762 @default.
• W2556227380 hasAuthorship W2556227380A5058765211 @default.
• W2556227380 hasAuthorship W2556227380A5060509370 @default.
• W2556227380 hasAuthorship W2556227380A5064710359 @default.
• W2556227380 hasAuthorship W2556227380A5066576514 @default.
• W2556227380 hasAuthorship W2556227380A5068769311 @default.
• W2556227380 hasAuthorship W2556227380A5071803772 @default.
• W2556227380 hasAuthorship W2556227380A5077428267 @default.
• W2556227380 hasAuthorship W2556227380A5086614200 @default.
• W2556227380 hasAuthorship W2556227380A5087294312 @default.
• W2556227380 hasAuthorship W2556227380A5087360250 @default.
• W2556227380 hasAuthorship W2556227380A5088355904 @default.
• W2556227380 hasConcept C126322002 @default.
• W2556227380 hasConcept C141071460 @default.
• W2556227380 hasConcept C143998085 @default.
• W2556227380 hasConcept C2776694085 @default.
• W2556227380 hasConcept C2777058707 @default.
• W2556227380 hasConcept C2777063308 @default.
• W2556227380 hasConcept C2779338263 @default.
• W2556227380 hasConcept C2780653079 @default.
• W2556227380 hasConcept C509974204 @default.
• W2556227380 hasConcept C71924100 @default.
• W2556227380 hasConcept C90924648 @default.
• W2556227380 hasConceptScore W2556227380C126322002 @default.
• W2556227380 hasConceptScore W2556227380C141071460 @default.
• W2556227380 hasConceptScore W2556227380C143998085 @default.
• W2556227380 hasConceptScore W2556227380C2776694085 @default.
• W2556227380 hasConceptScore W2556227380C2777058707 @default.
• W2556227380 hasConceptScore W2556227380C2777063308 @default.
• W2556227380 hasConceptScore W2556227380C2779338263 @default.
• W2556227380 hasConceptScore W2556227380C2780653079 @default.
• W2556227380 hasConceptScore W2556227380C509974204 @default.
• W2556227380 hasConceptScore W2556227380C71924100 @default.
• W2556227380 hasConceptScore W2556227380C90924648 @default.
• W2556227380 hasLocation W25562273801 @default.
• W2556227380 hasOpenAccess W2556227380 @default.
• W2556227380 hasPrimaryLocation W25562273801 @default.
• W2556227380 hasRelatedWork W198032405 @default.
• W2556227380 hasRelatedWork W2039180889 @default.
• W2556227380 hasRelatedWork W2150631566 @default.
• W2556227380 hasRelatedWork W2291378977 @default.
• W2556227380 hasRelatedWork W2464798367 @default.
• W2556227380 hasRelatedWork W2465205173 @default.
• W2556227380 hasRelatedWork W2522713853 @default.
• W2556227380 hasRelatedWork W2551032005 @default.
• W2556227380 hasRelatedWork W2551903713 @default.
• W2556227380 hasRelatedWork W2552758904 @default.
• W2556227380 hasRelatedWork W2557870693 @default.
• W2556227380 hasRelatedWork W2558604142 @default.
• W2556227380 hasRelatedWork W2569885932 @default.
• W2556227380 hasRelatedWork W2576281162 @default.
• W2556227380 hasRelatedWork W2588301057 @default.
• W2556227380 hasRelatedWork W2588908622 @default.
• W2556227380 hasRelatedWork W2594820239 @default.
• W2556227380 hasRelatedWork W3196876910 @default.
• W2556227380 hasRelatedWork W3210467067 @default.
• W2556227380 hasRelatedWork W1511199809 @default.
• W2556227380 isParatext "false" @default.
• W2556227380 isRetracted "false" @default.
• W2556227380 magId "2556227380" @default.
• W2556227380 workType "article" @default.